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Introduction 65
Tauopathies are a heterogeneous class of diseases characterized by cellular accumulation of 66 aggregated tau. Alzheimer's disease (AD) is the most prevalent tauopathy currently affecting 67 approximately 50 million people worldwide (1). Whereas AD is also characterized by 68 extracellular plaques composed of aggregated fibrillar amyloid-β (Aβ), other tauopathies such 69 as corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Pick's disease 70 (PiD), chronic traumatic encephalopathy (CTE), and aging-related tau astrogliopathy 71 (ARTAG) are primarily characterized by tau pathology (2,3). Interestingly, the morphology of 72 the cellular aggregates and affected cell types can vary between these diseases. For example, 73 while AD mainly features neurofibrillary tangles (NFTs) and neuropil threads (NTs) within 74 neurons, together with dystrophic neurites surrounding Aβ plaques (4), PSP and CBD present 75 with prominent astrocytic and oligodendroglial tau pathology ( Figure 1) (3). The different 76 tauopathies also have distinct anatomical distribution of pathology and present as unique 77 clinical syndromes (3). Due to its close correlation with neurodegeneration and cognitive 78 symptoms (5,6), there is a growing interest in the biology of tau propagation throughout the 79 human brain in different tauopathies. This review provides an AD-focused overview of the 80 literature, with the goal of integrating the existing knowledge obtained from human post 81 mortem studies, animal models, tau positron emission tomography (PET) and fluid 82 biomarkers. 83 84
Tau pathobiology 85
Tau protein is the major constituent of NFTs in AD (7-10) and the lesions found in PSP and 86
PiD (11) (12) (13) . Tau is an abundant axonal microtubule-binding protein with a variety of 87 physiological functions (14) . It can be subdivided into several domains: the structurally 88 disordered N-terminal, the proline rich mid-domain and the highly conserved C-terminal 89 domain ( Figure 2 ) (15-17). The C-terminal half of the protein contains the microtubule 90 binding repeats (MTBR), which are partly incorporated into the core of tau filaments (17) (18) (19) (20) . 91 Tau protein is encoded by the MAPT gene on chromosome 17q21.31 and various mutations in 92 this gene have been linked to an increased risk of tau pathology and clinical symptoms, 93 thereby strongly indicating tau pathology as causal to neurodegeneration (21-23). The MAPT 94 gene mRNA in the central nervous system can be alternatively spliced to encode six isoforms 95 of the tau protein, containing either 0, 1 or 2 N-terminal inserts and 3 or 4 MBTRs (24, 25) . 96
The difference between the 3R and 4R isoforms is that the 4R isoform includes the second 97 repeat encoded by exon 10, which is spliced out in 3R tau. Tau protein is subject to many 98 post-translation modifications (PTMs), such as phosphorylation, acetylation and truncation 99 (14) . Interestingly, it was already discovered early on that the tau proteins incorporated in the 100 fibrils are hyperphosphorylated (25). The precise role of PTMs in the initiation of tau 101 pathology is currently unresolved. However, several studies indicate that N-and C-terminal 102 truncation of tau may be an important early event in tangle formation and truncated tau 103 potently induces neurofibrillary degeneration in transgenic animals (26-28). 104
Insights into structural features of tau that are involved in the aggregation process 105 have been obtained by studying recombinant tau in vitro. Although a natively unfolded 106 protein, tau does appear to have a global physiological structure in which the C-terminal folds 107 over the MBTR and both ends of the molecule approach each other (29). The MTBR of tau 108 contains two hexapeptides that can form intermolecular β-sheet rich structures: aa275-280 109 (VQIINK) in R2 and aa306-311 (VQIVYK) in R3 (30,31). Under pathological conditions, tau 110 can adopt an abnormal conformation that exposes these residues and increases its propensity 111 for self-aggregation (32, 33). Physiological tau monomers can be incorporated into 112 aggregates; this process is known as templated misfolding or seeded-nucleation, and results in 113 the rapid elongation of aggregates (34). The seeding process starts with the misfolding and 114 6 aggregation of tau monomers, which then form the building unit for the formation of 115 oligomers and ultimately highly structured fibrils that are insoluble in detergents such as 116 sarkosyl (34, 35) . In AD, these tau filaments can take the form of paired helical filaments 117 (PHFs) and straight filaments (SFs), which accumulate as a mixture within the cell in the form 118 of NFTs (36). 119
Tau research is increasingly focused on the highly reactive detergent-soluble 120 oligomers, rather than the relatively inert larger detergent-insoluble fibrils (37). In AD, 121 neurons with NFTs can survive for decades (38). Additionally, neuronal loss correlates with 122 but exceeds NFTs in AD (39,40). Furthermore, suppression of tau overexpression in a mouse 123 model with aggressive tauopathy led to rescue of neurodegeneration and cognitive deficits. 124
Interestingly, NFTs continued to develop, indicating that the toxicity mainly originates from 125 soluble tau that is not sequestered by insoluble tau fibrils (41). Indeed, overexpression of an 126 aggregation prone version of tau rapidly induced the formation of Gallyas-positive NFTs, but 127 reduced the neurotoxicity of soluble tau (42). It is still conceivable that larger tau aggregates 128 may exert toxicity by taking up space in the crowded environment of the cell. However, the 129 soluble oligomers can easily diffuse throughout the cell, interact in a non-physiological 130 manner with a wide range of cellular proteins and cause synaptotoxicity (43). 131 7 endocytosis (57, 58). After tau seeds enter the neuron, they can leak via damaged vesicles into 140 the cytosol and seed physiological monomers to propagate the pathological process (59, 60). 141
Additionally, microglia and astrocytes can phagocytose extracellular tau and are involved in 142 tau spreading (61-63). The process of tau spreading is now hypothesized to underlie the 143 progression of tau pathology throughout the brain (Figure 3) . 144 145 Findings from post mortem patient studies using in vitro biosensor assays and structural 146 biology 147
A seminal post mortem study in 1991 described the stereotypical appearance and progression 148 of tau pathology in AD (64), which was later associated with the progression of cognitive 149 symptoms (65). This pattern was developed into a staging scheme based on the histological 150 detection of NFTs and subsequent cross-sectional comparisons between AD brain tissue at 151 different disease stages and is widely used in the research field (64) ( Figure 3 ). Beginning in 152 the rostral medial temporal lobe (specifically the entorhinal cortex, Braak I/II), tau pathology 153 is thought to then progress to limbic regions (Braak III/IV), including the hippocampus. Tau 154 pathology ultimately reaches the neocortex (Braak V/VI), which is invariably associated with 155 cognitive symptoms (65). The primary motor and sensory cortices can remain spared even at 156 these stages. Tau-associated neurodegeneration of the entorhinal cortex is thought to lead to a 157 functional disconnection of the hippocampal formation from the cortical association areas, a 158 process which may underlie the cognitive symptoms in AD (66). 159
It is currently unclear why the entorhinal cortex is particularly vulnerable to tau 160 pathology and neurodegeneration in AD. Tau pathology in AD always seems to affect the 161 same cell type, i.e. the large excitatory pyramidal cells in layer II of the entorhinal cortex that 162 project via the performant pathway to the hippocampus. It has been proposed that the regional 163 vulnerability of these neurons in the entorhinal cortex stems from their high metabolic rate 164 due to high dendritic complexity, long unmyelinated axons, high degrees of plasticity and 165 unique gene expression signature related to tau homeostasis (67-70). It is worth noting that 166 tau pathology in the primary tauopathies starts in different brain regions and additionally 167 affects glial cells. Recent progress has, for example, been made in staging the progression of 168 astrocytic tau pathology in ARTAG (71). This raises the question of how and why selective 169 regional vulnerability to tau pathology differs between different tauopathies. CTE is unique in 170 this regard, because the tau pathology is induced by external trauma, leading to individualized 171 progression patterns, that start in the cortex and later progress to the hippocampus and other 172 brain regions (72). 173
It was originally assumed that the progression of tau pathology throughout the rest of 174 the brain was mediated by regional vulnerability. As mentioned previously, however, there is 175 now accumulated evidence that tau aggregates can spread along neuronal connections and 176 lead to templated misfolding in healthy cells (73). A sensitive Förster resonance energy 177 transfer (FRET)-based biosensor assay was developed by Mark Diamond and is now widely 178 used to measure tau seeding in brain samples (74) . Several studies that have compared 179 neuropathology and tau seeding using this assay at different Braak stages in AD patients have 180
shown that tau seeding can be detected before overt tau pathology in the entorhinal cortex and 181 connected neuroanatomical regions (75, 76). Furthermore, seed-competent tau was isolated 182 from white matter tracts, indicating tau seeds can be transported along neuronal connections 183 (77). The same study also detected seed-competent tau in synaptosomes from AD patients, 184 which were isolated from brain regions that have not yet demonstrated tau pathology (77). 185
Though some authors have hypothesized that tau pathology starts in the locus coeruleus, no 186 tau seeding was observed in this area in early Braak stages (76). Two recent studies used size-187 exclusion chromatography to isolate a high molecular weight (HMW) tau species from AD 188 brain tissue and cerebrospinal fluid (CSF), which constituted only a small fraction of total tau 189 but was highly seed-competent and spread efficiently to other cells (78, 79). Tau isolated from 190 AD cases with Aβ plaque pathology was more seed-competent than tau from a case without 191 plaques; this could be experimentally explained by an increased proportion of HMW tau in 192 the presence of plaque pathology (80). 193
A recent study also used FRET-based cellular biosensor assay to demonstrate that 194 primary microglia, derived from patients with AD or other tauopathies, secrete seed-195 competent tau into the extracellular space (63). The results of this study suggest that while 196 microglia phagocytose extracellular tau, they seem unable to fully degrade it, secreting it back 197 into the extracellular space; in this way, microglia may contribute to the propagation of tau 198 pathology (63). The region-dependent differences in phagocytic capacity and the sensitivity of 199 this process to aging (81, 82) may provide a link between regional vulnerability and tau 200 spreading. 201
As mentioned previously, there is considerable heterogeneity in tau pathology across 202 tauopathies. Recent cryo-electron microscopy studies have provided unprecedented insight 203 into how structural differences in aggregates may lead to these differences. Tau filaments 204 extracted from the brain of an AD patient showed that the core is located at residues 306-378 205 and that the configuration of PHFs and SFs are slightly different (83). These residues are in 206 the third and fourth repeat and part of the distal C-terminus, which may explain why both 3R 207 and 4R tau can be incorporated into AD fibrils. The core of filaments from CTE is also 208 located in the third and fourth repeat, and they thereby also consist of both 3R and 4R tau. 209
However, CTE filaments also exhibit a structure distinct from AD fibrils which encloses an 210 additional density that is not connected to tau (84). This suggests that tau pathology in CTE 211 may be caused a cellular co-factor that promotes nucleation. On the other hand, filaments 212 derived from PiD tissue adopt a radically different fold compared to AD or CTE, with the 213 core between residues 254 and 378 and an inability to incorporate 4R tau isoforms (85). These 214 filaments also expose surface residues and phospho-epitopes that are distinct from AD 215 filaments (85). Data on 4R tauopathies such as PSP or CBD are not yet available, but this will 216
likely reveal yet another fold that excludes the 3R isoform. Important outstanding questions 217 are what biophysical mechanisms cause tau to fold into distinct filaments, why this happens in 218 distinct brain regions in different tauopathies and what explains the presence or absence of 219 glial tau pathology in the different tauopathies. 220
221
Animal-based tau spreading models 222
Animal models of tauopathy have significantly advanced our understanding of tau 223 pathobiology. In vivo spreading models can be roughly subdivided into three groups: 1) 224 transgenic models, 2) viral vector models and 3) seeding models (Table 1) . Transgenic 225 models overexpress human tau or its fragments that usually have mutations or amino acid 226 deletions that increase the propensity of tau to aggregate. Transgenic models are widely used 227 to study tau pathology, neuroinflammation and tau-associated neurodegeneration (86). With 228 an increased focus on tau spreading, transgenic models have been developed that selectively 229 express the transgene in the entorhinal cortex (87, 88). These models show spreading of 230 human tau to neighbouring and synaptically connected neurons, albeit only at advanced ages 231 (12 to 21 months). These models have for example been used to show that the presence of Aβ 232 deposition accelerates the propagation of tau (89). Additionally, optogenetically increasing 233 the activity of neurons in the entorhinal cortex speeds up spreading in this model (90). 234 Viral vector models are a practical improvement upon transgenic spreading models, as 235 they have been shown to induce spreading from the entorhinal cortex to the dentate gyrus in 236 as little as four weeks after injection (61). An adeno-associated virus (AAV) model has for 237 example been used to show that when microglia were depleted, spreading was greatly 238 diminished, thereby providing the first evidence that microglia play an important role in tau 239 propagation (61). An advantage of AAV models is that they can be modified to express both 240 human tau and fluorophores in a 1:1 ratio without fusing the proteins, thereby labelling the 241 transduced cells (91). This method provides strong evidence for spreading, as it is unlikely 242 that the synaptically connected cells were transduced by the AAV if they lack the 243 fluorophore. AAV models can also be easily combined with existing transgenic models to 244 study the mechanisms behind tau spreading, such as how proteins in pathways related to AD 245 risk genes (e.g. DAP12) affect tau propagation (92). 246
Another interesting approach is to induce pathology and spreading by injecting 247 aggregated tau isolated from the brains of transgenic animals or tauopathy patients into mouse 248 and rat tauopathy models (93-97). The introduction of existing fibrils bypasses the need for 249 nucleation, which is the rate-limiting step in the aggregation process. These fibrils can 250 therefore immediately seed overexpressed human tau or physiological mouse tau. The 251 spreading in these models was predominantly observed along neuronal connections, 252
indicating that synaptic spreading is the dominant mode of tau propagation (98). In an 253
interesting study tau aggregates were isolated from seeded cells in vitro, then injected in 254 animals and the brain lysates were applied to cells again. By creating several tau "strains", 255 this study demonstrated that the conformations of different types of tau aggregates can be 256 stably maintained when repeating this process multiple times (99) A follow-up study also 257 showed that different strains lead to unique cellular pathologies, aggregation properties and 258 anatomical spreading patterns (100). 259
Intriguingly, this strain hypothesis is now being extended by showing that tau isolated 260 from AD patients or patients with primary tauopathies (e.g. CBD, PSP) led to recapitulation 261 of the original tau pathology in these diseases (e.g. histopathological morphology and cell-262 type specificity) (93, 101). These models have now been refined to also induce tau pathology 263 in wild-type mice. These studies show that AD-derived tau filaments are more aggressive than 264 recombinant tau fibrils (102). In turn, tau filaments derived from CBD and PSP were more 265 aggressive than AD-derived tau fibrils and also induced astrocytic or oligodendrocytic tau 266 pathology (97). Since tau pathology originates in different brain regions in, for example, AD, 267 PSP and CBD, it would be interesting to see if the neurons or glial cells in these areas give 268 rise to the unique properties of the aggregates in these tauopathies. 269
When AD-derived tau filaments were injected in transgenic mice with Aβ plaque 270 pathology, this led to the formation of all three major types of AD tau pathology in an animal 271 model (i.e. NFTs, NTs, and tau aggregates in dystrophic neurites) (103, 104). This is 272 noteworthy because the range of tau pathologies observed in AD has not been observed in 273 previous transgenic mouse models expressing both Aβ and tau pathology (105). These studies 274 therefore demonstrate that mouse models that are injected with patient-derived fibrils possess 275 unique translational value in testing tau-based diagnostics and therapies. Indeed, a recent 276 study described the induction and hippocampal spreading of tau pathology induced by 277 injecting AD-derived tau filaments in a rat model overexpressing truncated tau (95). Given 278 the bigger brain size of rats compared to mice, such models might prove useful for studying 279 real-time tau spreading in vivo using PET imaging. 280 281
Tau PET imaging in humans 282
Though tau pathology is a challenging target for molecular imaging by means of PET (106) 283 -due to, for instance, the intracellular accumulation of tau and the varied ultrastructural 284 conformations it can assume -remarkable progress has been achieved in this area over the 285 past several years (107) (Figure 4 ). Using so-called first generation tau ligands (e.g. 286 have also shown discrimination from controls and regional uptake relatively consistent with 295 those expected in these diseases (109, 116,117), however, oftentimes ligand retention appear 296 in regions with known off-target binding, complicating accurate quantification. Given that 297 existing ligands seem to bind preferentially to AD-type 3R/4R PHF tau, however, it is likely 298 the case that a range of novel compounds will ultimately be needed to cover the spectrum of 299 primary tauopathies. 300
In the few studies hitherto addressing longitudinal tau PET in controls and AD 301 patients (118-122), increases in tau PET signal over time have been reported, with the greatest 302 increases consistently being observed in demented individuals. In the largest of these to date 303 (121), fairly uniform rates of tau accumulation were reported across brain regions, arguing 304 against the histopathology-derived idea that tau pathology necessarily aggregates in a 305 stepwise fashion. While not ruling out the concept that tau may spread trans-synaptically, this 306 finding does conflict with the idea that increases in the level of tau burden in the brain result 307 from its spread from one unaffected area to another. This discrepancy between the thus far 308 limited in vivo PET findings and histopathology may, however, be a reflection of the fact that 309 current ligands lack extensive validation (123) or the fact that the Braak tau staging scheme 310 amounts to an extrapolation due to it being grounded in cross-sectional autopsy data. 311 312 313
Measures of tau in body fluids 314
Core CSF biomarkers for AD include total tau (T-tau) and tau phosphorylated at threonine 315 181 (P-tau). Numerous clinical studies have consistently shown a marked increase in both in 316 AD, and in patients with mild cognitive impairment (MCI) (124). These CSF biomarkers are 317 now, together with CSF Aβ42 that reflects brain amyloidosis (125) 
Conclusion and outlook 355
Interest in how tau pathology progresses through the brain has been a subject of research 356 since the initial development of the staging scheme for tau pathology by Braak and Braak. 357 The discovery of tau spreading in cellular and animal models has led to a surge of scientific 358 efforts on this topic in the past decade (96). There has been significant progress in humanizing 359 animal tauopathy models; by injecting patient-derived tau fibrils as seeds into rodent brains, 360 the aggregation, histopathological lesions and cell-type specificity of the patient can be 361 recapitulated. Such models may provide better translatability to study the mechanisms of tau 362 pathology in vivo and are increasingly used to test novel therapeutics (148, 149). Important 363 outstanding questions that can be studied with these models are for example how microglia, 364 astrocytes and other cells types are involved in the progression of tauopathy. 365
There have also been substantial developments in studying tau pathology at autopsy. 366
FRET-based cellular biosensor assays can detect tau seeding activity before misfolding or 367 hyperphosphorylation of tau, as detected by traditional histological means (e.g. MC1 or AT8 368 staining). Though these assays have mostly been applied to AD tissue, further studies in 369 primary tauopathies are required to examine differences in regional vulnerability and cell-to-370 cell spreading may vary among the tauopathies. As it is likely that neurons in certain 371 anatomical regions are more vulnerable to accumulating tau pathology after taking up 372 extracellular tau seeds, more studies are needed on the correlation between tau spreading and 373 the transcriptional profile of vulnerable regions. 374
While the possibility to regionally map and quantify tau pathology in vivo has been 375 introduced with tau PET ligands, more data are required for novel tau PET ligands, including 376 comparative studies with CSF measures of tau. Measuring T-and P-tau in CSF has been 377 possible for several decades and has ever since constituted an important diagnostic tool, 378 however, whether tau seeds in biofluids such as CSF could be used as clinically accessible 379 diagnostic biomarkers, needs to be established. Neuroscience SE, which develops tau-based immunotherapy. AL, CC and NJA report no 403 biomedical financial interests or potential conflicts of interest. 
